# Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4

> **NCT03381859** · PHASE4 · WITHDRAWN · sponsor: **University of Maryland, Baltimore**

## Conditions studied

- Hepatitis C Virus Infection, Response to Therapy of

## Interventions

- **DRUG:** Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]

## Key facts

- **NCT ID:** NCT03381859
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** HCV treatment expansion occurred in Egypt
- **Last updated:** 2020-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03381859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03381859, "Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03381859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*